GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Shiller PE Ratio

Incyte (BSP:I1NC34) Shiller PE Ratio : 55.02 (As of May. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Incyte Shiller PE Ratio?

As of today (2024-05-03), Incyte's current share price is R$135.90. Incyte's E10 for the quarter that ended in Mar. 2024 was R$2.47. Incyte's Shiller PE Ratio for today is 55.02.

The historical rank and industry rank for Incyte's Shiller PE Ratio or its related term are showing as below:

BSP:I1NC34' s Shiller PE Ratio Range Over the Past 10 Years
Min: 53.28   Med: 135.73   Max: 261.53
Current: 54.53

During the past years, Incyte's highest Shiller PE Ratio was 261.53. The lowest was 53.28. And the median was 135.73.

BSP:I1NC34's Shiller PE Ratio is ranked worse than
66.89% of 151 companies
in the Biotechnology industry
Industry Median: 34.81 vs BSP:I1NC34: 54.53

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Incyte's adjusted earnings per share data for the three months ended in Mar. 2024 was R$1.867. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is R$2.47 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Incyte Shiller PE Ratio Historical Data

The historical data trend for Incyte's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Shiller PE Ratio Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 245.29 155.17 72.06

Incyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.93 95.69 76.96 72.06 58.51

Competitive Comparison of Incyte's Shiller PE Ratio

For the Biotechnology subindustry, Incyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Shiller PE Ratio falls into.



Incyte Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Incyte's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=135.90/2.47
=55.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Incyte's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.867/129.4194*129.4194
=1.867

Current CPI (Mar. 2024) = 129.4194.

Incyte Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.246 100.560 -0.317
201409 0.386 100.428 0.497
201412 -0.291 99.070 -0.380
201503 -0.173 99.621 -0.225
201506 0.078 100.684 0.100
201509 -0.429 100.392 -0.553
201512 0.563 99.792 0.730
201603 0.222 100.470 0.286
201606 0.308 101.688 0.392
201609 0.309 101.861 0.393
201612 0.084 101.863 0.107
201703 -1.501 102.862 -1.889
201706 -0.099 103.349 -0.124
201709 0.266 104.136 0.331
201712 -1.170 104.011 -1.456
201803 -0.312 105.290 -0.384
201806 0.453 106.317 0.551
201809 0.288 106.507 0.350
201812 0.621 105.998 0.758
201903 0.903 107.251 1.090
201906 0.925 108.070 1.108
201909 1.215 108.329 1.452
201912 1.047 108.420 1.250
202003 -8.136 108.902 -9.669
202006 3.424 108.767 4.074
202009 -0.189 109.815 -0.223
202012 1.749 109.897 2.060
202103 0.676 111.754 0.783
202106 1.685 114.631 1.902
202109 2.164 115.734 2.420
202112 7.182 117.630 7.902
202203 0.423 121.301 0.451
202206 1.817 125.017 1.881
202209 1.311 125.227 1.355
202212 0.341 125.222 0.352
202303 0.260 127.348 0.264
202306 2.184 128.729 2.196
202309 1.877 129.860 1.871
202312 2.180 129.419 2.180
202403 1.867 129.419 1.867

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incyte  (BSP:I1NC34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Incyte Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Incyte's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (BSP:I1NC34) Business Description

Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (BSP:I1NC34) Headlines

No Headlines